A wholly-owned subsidiary of Menovo, Ningbo Menovo Tiankang Pharmaceutical Co., Ltd., was founded in 2010 and has a footprint of around 56000 square meters. As the main preparation platform within the group, it carries the key link of the company's API-preparation integration. Its products are mainly solid preparations sold to the Chinese market and the European market.
At present, the company has an annual production capacity of 1.5 billion tablets (capsules). The production capacity of workshop three is being promoted and the anti-tumor preparation workshop with the synchronous layout in phase I is 3 billion tablets (capsules). After the completion of phase II of workshop three, the total production capacity is about 7.5 billion tablets (capsules).